BioCardia, Inc. (BCDA)

Market Cap	13.58M +47.4%
Revenue (ttm)	n/a -87.8%
Net Income	-8.54M
EPS	-1.66
Shares Out	10.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	212,672
Open	1.280
Previous Close	1.270
Day's Range	1.240 - 1.410
52-Week Range	1.000 - 3.200
Beta	0.55
Analysts	Strong Buy
Price Target	25.00 (+1,853.13%)
Earnings Date	Apr 1, 2026

About BCDA

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company’s lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bon...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Peter Altman
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: BCDA
• Website: https://www.biocardia.com

Financial Performance

In 2024, BioCardia's revenue was $58,000, a decrease of -87.84% compared to the previous year's $477,000. Losses were -$7.95 million, -31.33% less than in 2023.

Analyst Summary

According to one analyst, the rating for BCDA stock is "Strong Buy" and the 12-month stock price target is $25.0.

Price Target

$25.0

(1,853.13% upside)

Analyst Consensus: Strong Buy